Why acute viral hepatitis should occasionally pursue a fulminant course is poorly understood. In hepatitis B virus (HBV) infections there is evidence of an enhanced antibody response to the surface antigen (HBsAg) with a more rapid appearance of anti-HBs in blood and a shorter period of HBs antigenaemia in patients with a fulminant course compared with those with uncomplicated hepatitis. ' 
Results
Sera from patients with uncomplicated hepatitis were all HBsAg positive whereas in the group with fulminant hepatic failure two patients were HBsAg negative (<0.5 ng/ml). The concentrations of HBsAg in the group with fulminant hepatic failure were significantly lower than those with uncomplicated hepatitis (median 0.64 ,ug, range 16-0 ,ug, and median 32 ,ug and range 100-4 ,ug, respectively, p<0.001). In the fulminant hepatic failure group the two patients who were HBsAg negative had detectable anti-HBs in the serum. In contrast, anti-HBs was not found in any of the admission samples from patients with uncomplicated hepatitis.
HBeAg was present in the admission sample from only two of the 17 patients with fulminant hepatic failure (12%) but was found in all but two (88%) admission samples from the 17 patients with acute hepatitis (p<0-001). Anti-HBe was present in sera from two patients with fulminant hepatic failure. In one, the HBsAg concentration was low (40 ng/ml) and in the other, which was one of the two HBsAg-negative sera, anti-HBs was already also present. In contrast, anti-HBe was not detected in the admission sample of any patient with uncomplicted acute hepatitis.
All 34 patients had diagnostic levels of anti-HBc IgM though the median levels were significantly higher in the fulminant hepatic failure group, 500 arbitrary IU/ml, compared with the group with uncomplicated hepatitis, 202 arbitrary IU/ml (p<005, Wilcoxon's rank test, Figure) The cause of this heightened antibody production is unclear. As three immunologically distinct antigens are involved it is unlikely to be due to an immune response gene, which, as currently understood, controls the response to a single antigen. Rather, the response is likely to be part of a generalised increase in immune responsiveness to many antigens, including those specific to HBV.
Th rapid disappearance of HBsAg in patients with fulminant hepatic failure may make the diagnosis of an acute HBV infection difficult. Both anti-HBs and anti-HBc may be detected for months or 
hepatitis B.
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